Supply Chain Intelligence

Sangamo Therapeutics, Inc. Supply Chain

SGMO supply chain intelligence for Sangamo Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SGMO ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
21Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Sangamo Therapeutics, Inc. (SGMO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

32Total relationships
2Distinct source URLs
12High confidence
0.766Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Sangamo Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
CELU Celularity Inc. 72% Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demo…
MGX Metagenomi Therapeutics, Inc. 72% Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, t…
NKTR Nektar Therapeutics 72% Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the developmen…
NTLA Intellia Therapeutics, Inc. 72% Reciprocal relationship from NTLA graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain a…
PLX Protalix BioTherapeutics, Inc. 72% Reciprocal relationship from PLX graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PLX graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PLX grap…
PRME Prime Medicine, Inc. 72% Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteris…
VOR Vor Biopharma Inc. 72% Reciprocal relationship from VOR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be av…

Sangamo Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
ALEXION-PHARMACEUTICALS-INC ALEXION-PHARMACEUTICALS-INC 90% In October 2023, Pfizer notified us that it had assigned to Alexion the collaboration and license agreement between Sangamo and Pfizer for the development and commercialization of potential gene ther…
MILTENYI-BIOTEC-B-V-CO-KG MILTENYI-BIOTEC-B-V-CO-KG 90% Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March 31, 2026 and 2025 were as follows: Three Months Ended March 31, 2026 2025 Milteny…
SIGMA-ALDRICH-CORPORATION SIGMA-ALDRICH-CORPORATION 90% These license partners include Corteva AgriScience, formerly known as Dow AgroSciences LLC, or DAS, Sigma-Aldrich Corporation (now MilliporeSigma in the United States and Merck KGaA outside the Unite…
TAKEDA TAKEDA 90% Pursuant to the amended and restated agreement, Takeda has an exclusive, worldwide license to ZF therapeutics for treating Huntington’s disease.
CORTEVA-AGRISCIENCE CORTEVA-AGRISCIENCE 85% These license partners include Corteva AgriScience, formerly known as Dow AgroSciences LLC, or DAS, Sigma-Aldrich Corporation (now MilliporeSigma in the United States and Merck KGaA outside the Unite…
MERCK-KGAA MERCK-KGAA 85% These license partners include Corteva AgriScience, formerly known as Dow AgroSciences LLC, or DAS, Sigma-Aldrich Corporation (now MilliporeSigma in the United States and Merck KGaA outside the Unite…
OPEN-MONOCLONAL-TECHNOLOGY-INC OPEN-MONOCLONAL-TECHNOLOGY-INC 85% These license partners include Corteva AgriScience, formerly known as Dow AgroSciences LLC, or DAS, Sigma-Aldrich Corporation (now MilliporeSigma in the United States and Merck KGaA outside the Unite…
ROCHE-GROUP ROCHE-GROUP 85% ly of revenues from collaboration agreements, including upfront license fees, reimbursements for research services, and milestone achievements, and research grant funding. In 2025, we entered into li…
LGND Ligand Pharmaceuticals Incorporated 72% eements 6 % 2 % Accounts Receivable Accounts receivable consists of amounts billed to the Company’s collaboration partners for cost reimbursements for research services, sublicensing revenue, and roy…
LGND Ligand Pharmaceuticals Incorporated 72% Reciprocal relationship from LGND graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from LGND graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from LGND g…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from SGMO graph: significant to the fair value measurements and unobservable ( i.e., supported by little or no market activity). The Co…
LLY Eli Lilly and Company 72% significant to the fair value measurements and unobservable ( i.e., supported by little or no market activity). The Company had no marketable securities as of December 31, 2025 and 2024. The Company …
MGX Metagenomi Therapeutics, Inc. 72% Reciprocal relationship from MGX graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX grap…
NKTR Nektar Therapeutics 72% Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the developmen…
PRME Prime Medicine, Inc. 72% Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME g…
VOR Vor Biopharma Inc. 72% Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any…
ASTELLAS-GENE-THERAPIES-INC ASTELLAS-GENE-THERAPIES-INC 62% es have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact tha…
DOW Dow Inc. 62% Reciprocal relationship from DOW graph: Reciprocal relationship from SGMO graph: gent on the achievement of specified preclinical development, clinical development and first commercial sale milestone…
DOW-AGROSCIENCES-LLC DOW-AGROSCIENCES-LLC 62% gent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $ 90.0 million in commercial milestone payments if annual worldwide …
DOW-CHEMICAL-COMPANY DOW-CHEMICAL-COMPANY 62% gent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $ 90.0 million in commercial milestone payments if annual worldwide …
WELLS-FARGO-SECURITIES-LLC WELLS-FARGO-SECURITIES-LLC 62% gent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $ 90.0 million in commercial milestone payments if annual worldwide …

Sangamo Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SGMO-DEBT-12508 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
SGMO-DEBT-12507 Warrants outstanding: 0.75 90% xbrl warrant detail from xbrl 2025-09-30.
SGMO-DEBT Debt stack $19.3M 90% Market cache reports total debt of $19.3M.

Sangamo Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Sangamo Therapeutics, Inc..

Sangamo Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
SGMO-OWNER-ARMISTICE-CAPITAL-LLC ARMISTICE CAPITAL, LLC 90% 13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 114 tracked holders.

Sangamo Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SDGR Schrödinger, Inc. 100.00 2
CRMD CorMedix Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
ATRA Atara Biotherapeutics, Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
LGND Ligand Pharmaceuticals Incorporated 100.00 1 ['customer']
EDIT Editas Medicine, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Sangamo Therapeutics, Inc..

Unlock full SGMO data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
SGMO
Unlock SGMO Supply Chain Data
Verified relationships include:
CELUCelularity Inc.Supplier72%
MGXMetagenomi Therapeutics, Inc.Supplier72%
ALEXION-PHARMACEUTICALS-INCALEXION-PHARMACEUTICALS-INCCustomer90%
MILTENYI-BIOTEC-B-V-CO-KGMILTENYI-BIOTEC-B-V-CO-KGCustomer90%
+28 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →